Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: 5T4 x CD3 DART; DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; JNJ-9383; MGD 015; MGD 019; MGD-15; PD-1 x CTLA-4 bispecific DART molecule; ROR1xCD3 DART

Latest Information Update: 28 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen modulators; Interleukin 13 receptor modulators; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 08 Nov 2017 MacroGenics announces intention to submit IND application to the US FDA for MGD 019 in Cancer in 2018
  • 31 Aug 2017 Janssen plans a first-in-human phase I trial of MGD 015 for Cancer in 2018
  • 01 Apr 2017 Pharmacokinetics data from preclinical studies in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top